Bristol Myers Squibb is expected to announce Monday that it has formally submitted a request for FDA priority review designation for mezigdomide (mezigdomide plus carfilzomib and dexamethasone, MeziKd) in relapsed and refractory multiple myeloma, capitalising on strong clinical data presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago over the weekend.

The company reported that MeziKd reduced the risk of disease progression or death by 52% compared with standard-of-care regimens, with response rates exceeding expectations across multiple patient subgroups including those with high-risk cytogenetics and prior lenalidomide exposure. Oncology analysts attending the ASCO meeting described the data as among the most compelling myeloma readouts of the conference, with several flagging the results as potentially practice-changing for a disease segment with limited options after two or more prior lines of therapy.

In a statement expected to be issued from BMS's Princeton, New Jersey headquarters, the company's chief medical officer is anticipated to describe the ASCO data as the foundation for an accelerated regulatory pathway. The company has indicated it will seek priority review under the FDA's Breakthrough Therapy designation framework, which mezigdomide already holds for this indication. An FDA priority review decision, if granted, would reduce the standard 12-month review clock to six months and signal the agency's recognition of the drug's potential to address an unmet medical need.

Wall Street analysts at JPMorgan and SVB Securities revised their peak sales estimates for mezigdomide upward following Sunday's data presentation, with several now projecting annual revenues exceeding $2.5 billion if the drug secures a broad label. BMS shares were positioned for gains at Monday's open, with options markets reflecting increased activity in the stock heading into the trading week.

The myeloma community has watched mezigdomide's development closely as a next-generation cereblon E3 ligase modulator, or CELMoD agent, designed to overcome resistance to older immunomodulatory drugs such as lenalidomide. If approved, it would join BMS's established myeloma portfolio and extend the company's dominance in a therapeutic area where it already markets Revlimid and Pomalyst. Patient advocacy groups including the Multiple Myeloma Research Foundation have expressed cautious optimism, noting that the subgroup data suggesting benefit in lenalidomide-refractory patients could meaningfully expand treatment options for one of the hardest-to-treat myeloma populations.